Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVEX: Bevacizumab + Capecitabine in Elderly mCRC
NCT00484939Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2007
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free Survival. Started Jul 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00484939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00484939.